WI
SRPT icon

WBI Investments’s Sarepta Therapeutics SRPT Stock Holding History

WBI Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,064
Closed -$1.72M – 229
2020
Q4 		$1.72M Buy
+10,064
New +$1.49M 0.26% 81

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

WBI Investments's SRPT Position: Q1 2021 in Review

WBI Investments sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 10,064 shares — an estimated $1.72M sold.

WBI Investments first reported a position in SRPT in Q4 2020 and held it in 1 quarter. The position peaked at $1.72M in Q4 2020. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

  • WBI Investments reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
  • WBI Investments sold 10,064 Sarepta Therapeutics shares in Q1 2021, an estimated $1.72M.
  • WBI Investments first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 1 quarter.
  • WBI Investments's Sarepta Therapeutics position peaked at $1.72M in Q4 2020.
  • 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on WBI Investments's 13F filing for Q1 2021, filed 12 May 2021.